| scholarly article | Q13442814 |
| P2093 | author name string | Hyung Joon Kim | |
| Jong Jin Lee | |||
| Eun Kyung Baek | |||
| Dae Geon Ahn | |||
| EunYoung Ze | |||
| Han Wook Chung | |||
| Hwan Jun Cho | |||
| HyunWoong Lee | |||
| Jae Cheol Kwon | |||
| P2860 | cites work | Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine | Q33206221 |
| Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. | Q54599747 | ||
| Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B | Q83258052 | ||
| Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil | Q33233245 | ||
| Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy | Q33417353 | ||
| Management of viral hepatitis B. | Q33959006 | ||
| Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis | Q33985364 | ||
| Chronic hepatitis B. | Q34002160 | ||
| Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level | Q34481474 | ||
| Selecting appropriate management strategies for chronic hepatitis B: who to treat | Q36382648 | ||
| Entecavir: a new treatment option for chronic hepatitis B. | Q36413174 | ||
| Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach | Q37074608 | ||
| Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance | Q39988589 | ||
| Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection | Q41604155 | ||
| Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. | Q42551686 | ||
| Current treatment indications and strategies in chronic hepatitis B virus infection. | Q42619923 | ||
| Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. | Q42876001 | ||
| Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy | Q42957928 | ||
| Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues | Q43226767 | ||
| Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus | Q44709441 | ||
| Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. | Q44709445 | ||
| Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. | Q45023133 | ||
| Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient | Q45408115 | ||
| Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy | Q45414035 | ||
| Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up | Q46629124 | ||
| Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. | Q46913808 | ||
| Predicting cirrhosis risk based on the level of circulating hepatitis B viral load | Q46985831 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P921 | main subject | entecavir | Q418586 |
| lamivudine | Q422631 | ||
| chronic hepatitis B | Q55779876 | ||
| P304 | page(s) | 267-273 | |
| P577 | publication date | 2014-09-25 | |
| P1433 | published in | Clinical and molecular hepatology | Q26853927 |
| P1476 | title | Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir | |
| P478 | volume | 20 |
| Q28074579 | Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis |
| Q59355375 | Comparison of replication competence of wild-type and lamivudine-resistant hepatitis B virus isolates from a chronic hepatitis B patient |
| Q41327802 | The clinical implication of single nucleotide polymorphisms in deoxycytidine kinase in chronic hepatitis B patients treated with lamivudine |
Search more.